Pharvaris to Participate in BofA Securities 2022 Healthcare Conference

Rhea-AI Summary

Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on developing oral bradykinin-B2-receptor antagonists for treating hereditary angioedema (HAE), has announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas from May 10-12, 2022. The company's presentation is scheduled for May 12, 2022, at 10:00 AM PDT (7:00 PM CEST). A live webcast will be accessible on its website, with a replay available for 30 days post-event.

ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) --  Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in hereditary angioedema (HAE), today announced that management will present at the BofA Securities 2022 Healthcare Conference taking place in Las Vegas, NV from May 10 – 12, 2022.

Pharvaris’ presentation will take place at 10:00 AM PDT (7:00 PM CEST) on Thursday, May 12, 2022. A live webcast of the presentation will be available on the Investors section of the Pharvaris website at: https://ir.pharvaris.com/news-events/events-presentations. A replay will be available on Pharvaris’ website for 30 days following the presentation.

About Pharvaris
Pharvaris is a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks, building on its deep-seated roots in HAE. By directly targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE more effective and convenient alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.

Contacts
Pharvaris
Maryann Cimino
Director of Corporate Relations
maryann.cimino@pharvaris.com 
+1-617-710-7305

Investors
Sarah McCabe
sarah.mccabe@sternir.com
+1-212-362-1200

Media
Scott Stachowiak, Russo Partners, LLC
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630

 

FAQ

When will Pharvaris present at the BofA Securities 2022 Healthcare Conference?

Pharvaris will present on May 12, 2022, at 10:00 AM PDT (7:00 PM CEST).

How can I watch Pharvaris' presentation at the BofA Securities 2022 Healthcare Conference?

You can watch the presentation live on the Investors section of the Pharvaris website.

What is the focus of Pharvaris as a clinical-stage company?

Pharvaris is focused on developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent HAE attacks.

Is there a replay available for Pharvaris' conference presentation?

Yes, a replay of the presentation will be available on the Pharvaris website for 30 days after the event.

What is the stock symbol for Pharvaris?

Pharvaris is traded under the stock symbol PHVS.